MacViewer

Why is this important?

  • ARMD is the leading cause of blindness, occurring predominantly in those over age 55
  • While investigative drugs and procedures are showing promise, there is currently no cure
  • Studies have shown that early detection can lead to a better chance for reversal or at least slowing the advance
  • Advanced cases require surgery, which is not always successful in restoring vision

What is the MacViewer ?

A patented* method and device that enables early detection of irregularities in the macula and surrounding retinal region. This is often the result of the onset of Age-related Macular Degeneration (ARMD), but may also be caused by other diseases and conditions, such as Diabetic Retinopathy.

How does it work?

The MacViewer device generates a specific flashing color and light pattern which enables the patient to observe any irregularities that may be present in the macular region. Once the irregularities have been identified they can be documented and communicated or transmitted to a healthcare professional for review as necessary.

What are its advantages?

The MacViewer helps identify irregularities in the central visual field quickly, simply, and at an early stage of development, while the condition may still be readily treated with some of the new and emerging therapeutic methods. The device may also provide the ability to observe the effects of the therapeutic regimen, and therefore self-monitor progress and improvement.

When will it be available?

Pre-clinical tests and a multi-center trial with the method and device demonstrated positive results. We are now working on the design of a fifth prototype version of the product, and expect to have it completed soon.

We are working toward a crowdfunding campaign for the fall of 2022, and we’ll update with more information on this as we get closer to that time.

Scalar Bioscience is working to commercialize this important innovation, and is interested in working with companies who have complementary products for treating Macular Degeneration and other conditions of the central visual field.

* U.S. Patent 7,166,079. International Patents in Australia, Canada, and 6 EU countries issued.